Perdoceo Education Sells 33,271: What Investors Should Know
A CFO sold a sizable block of Perdoceo Education shares during a year of strong stock gains. This guide explains what...
What Moves Stock Indices
An overview of the major forces behind stock index movements, with guidance on tracking catalysts and assessing risk.
21,624 articlesJPMorgan Equity Premium Income: Is It Right for You
Curious about a strategy that blends stock ownership with option income? This deep-dive on the JPMorgan Equity Premiu...
Anterix Stock 140%. Here's Why One Investor Spent $15.8M
Anterix stock surged 140% as a major investor disclosed a multi-million dollar buy. This article breaks down the driv...
Ziff Davis' General Counsel Sale Signals Investor Impact
A senior executive at Ziff Davis sold a sizable block of shares. This article dives into what that move could mean fo...
Nike Wants Make Comeback: Buy Stock Before June 30
Nike is flirting with a comeback narrative as it gears up for June earnings. This guide breaks down what to watch, ho...
Here's Might Regret Buying SpaceX Stock Before Aug. 6
Investors are weighing SpaceX's first earnings as a public company against a backdrop of limited float and big hype. ...
What Does Magnite Insider's Sale Mean for Investors Today
A Magnite insider disclosed a sizable open-market sale, sparking questions for investors. This guide breaks down what...
Mason Capital Takes Position in BORR Stock: New Stake
A major hedge fund recently disclosed a new stake in BORR, signaling a strategic bet in the offshore drilling sector....
Rice Hall James Loads Up on Birkenstock: 466k Stake
A major institutional bet lands on Birkenstock. Rice Hall James loads 466,577 shares, a roughly $19.8 million stake i...
Should Micron Before Earnings? The One Thing That Matters
earnings week brings big questions for Micron. The real driver isn’t a guess on revenue alone—it's AI memory demand....
Kulicke Soffa Director Sold: What It Means for Investors
When a kulicke soffa director sold 20,000 shares for about $2 million, it prompts questions about insider intent and ...
Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Popular Topics
Fable
Smart Money Moves For Everyday Life
Investment Strategies In Energy Sector
Best Index Funds For Retirement
Investment Strategies
Untitled D6eff7ea
Crypto For Beginners
Best Dividend Etfs
Index
Innovative Skincare Clinical
Dutch Salary
Blue Owl
Budget
Ai Healthcare News
Penalty Vs No Penalty Depending On Lock Status